Valproate-induced hyperammonemic encephalopathy

Acta Neurologica Scandinavica

Volumn 114, Issue 1, 2006, Pages 1-7

  Segura Bruna, N ^a   Rodriguez Campello, A ^a   Puente, V ^a   Roquer, J ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Adverse effects; Antiepileptic drugs; EEG; Epilepsy; Inherited metabolic disorders; Molecular biology

Indexed keywords

2 PROPYL 4 PENTENOIC ACID; AMMONIA; CARBAMAZEPINE; CARBAMOYL PHOSPHATE SYNTHASE; CARNITINE; FLUOROURACIL; GLUTAMINE; IBUPROFEN; METHIONINE SULFOXIMINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE CARBAMOYLTRANSFERASE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PIVMECILLINAM; PROPIONIC ACID; SALICYLIC ACID DERIVATIVE; TOPIRAMATE; UREA; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMBLYOPIA; AMMONIA BLOOD LEVEL; ASTROCYTE; BIOCHEMISTRY; BRAIN DISEASE; BRAIN EDEMA; BRAIN LEVEL; CARNITINE DEFICIENCY; CELL SWELLING; CHRONOTHERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; COMA; CONFUSION; DELTA RHYTHM; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DROWSINESS; DRUG FEVER; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SCREENING; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; ENZYME DEFECT; ENZYME INHIBITION; FRONTAL LOBE; HALLUCINATION; HUMAN; HYPERAMMONEMIA; LETHARGY; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; RESTLESSNESS; REVIEW; REYE SYNDROME; RISK FACTOR; SEIZURE; SUPPLEMENTATION; THETA RHYTHM; TREATMENT RESPONSE; UNCONSCIOUSNESS; UREA CYCLE; VOMITING;

ANTICONVULSANTS; BRAIN; BRAIN EDEMA; CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING); CARNITINE; DIAGNOSIS, DIFFERENTIAL; GLUTAMIC ACID; GLUTAMINE; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; VALPROIC ACID;

EID: 33745038745     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00655.x     Document Type: Review

References (42)

1. Kay JD Hilton-Jones D Hyman N. Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet 1986 2 : 1283 4.
2. Hawkes ND Thomas GAO Jurewicz A et al. Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J 2001 77 : 717 22.
3. Elsas LJ Longo N Rosenberg LE. Enfermedades hereditarias del metabolismo de los aminoácidos y por depósito de los mismos. In : Fauci AS Harrison TR, eds. Principios de Medicina Interna. Interamericana de España, S.A.U. : McGraw-Hill, 1998 2497 500.
4. Oechsner M Steen C Stürenburg HJ Kohlscütterb A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry 1998 64 : 680 2.
5. O'Neil M Dubrey RW Grocott-Mason RM. Valproate encephalopathy and hyperammonaemia. Postgrad Med J 2002 78 : 316 7.
6. Hamer HM Knake S Schomburg U Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 54 : 230 2.
7. Verrotti A Trotta D Morgese D Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002 17 : 367 73.
8. Chen W-T Yen D-J Yu H-Y Liao K-K. Valproate-induced encephalopathy. Chin Med J 2001 64 : 474 8.
9. Ziyeh S Thiel T Spreer J Klisch J Schumacher M. Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia 2002 43 : 1101 5.
10. Takanashi J Kurihara A Tomita M et al. Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency. Neurology 2002 59 : 210 4.
11. Sobaniec-Lotowska ME. Ultrastructure of astrocytes in the cortex of the hippocampal gyrus and in the neocortex of the temporal lobe in experimental valproate encephalopathy and after withdrawal. Int J Exp Pathol 2003 84 : 115.
12. Sobaniec-Lotowska ME. Ultrastructure of synaptic junctions in the cerebellar cortex in experiments valproate encephalopathy and after terminating chronic application of the antiepileptic. Folia Neuropathol 2002 40 : 87 96.
13. Sobaniec-Lotowska ME. Ultrastructure of Purkinje cells and their dendritic processes in the rat cerebellar cortex in experimental encephalopathy induced by chronic application of valproate. Int J Exp Pathol 2001 82 : 337.
14. Gidal BE Inglese CM Meyer JF Pitterle ME Antonopolous J Rust RS. Diet-and valproate-induced transient hyperammonemia: effect of l-carnitine. Pediatr Neurol 1997 16 : 301 5.
15. Katano H Fukushima T Karasawa K Sugiyama N Ohkura A Kamiya K. Primidone-induced hyperammonemic encephalopathy in a patient with cerebral astrocytoma. J Clin Neurosci 2002 9 : 79 81.
16. Coulter DL Allen RJ. Secondary hyperammonemia: a possible mechanism for valproate encephalopathy. Lancet 1980 2 : 1310 1.
17. Code FX Rabier D Cathelinerau L Grimber G Parvy P Kamoun P. A mechanism for valproate-induced hyperammonemia. Adv Exp Med Biol 1982 153 : 153 61.
18. Holowach Thurston J Carroll JE Hauhart RE Schiro JA. A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: possible clinical significance. Life Sci 1985 36 : 1643 51.
19. Vainstein G Korzets Z Pomeranz A Gadot N. Deepening coma in a epileptic patient: the missing link to the urea cycle. Nephrol Dial Transplant 2002 17 : 1351 3.
20. Leao MMD. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology 1995 45 : 593 4.
21. Honeycutt D Callahan K Rutledge L Evans B. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 1992 42 : 666 8.
22. Tein I Xie ZW. Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 1994 204 : 753 8.
23. Stadler DD Bale JF Chenard CA Rebouche CJ. Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. Metabolism 1999 48 : 74 9.
24. Beversdorf D Allen C Nordgren R. Valproate-induced encephalopathy treated with carnitine in an adult. J Neurol Neurosurg Psychiatry 1996 61 : 211.
25. Bohan TP Helton E MacDonald I et al. Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001 56 : 1405 9.
26. Osuna MT Burcet J Ramió L Ustrell X Silva Y Molins A. Encefalopatía hiperamoniémica asociada al uso de valproato sódico. Neurologia 2003 18 : 347 50.
27. Sztajnkrycer MD. A reply to 'Carnitine' and 'Role of carnitine in valproic acid toxicity'. J Toxicol Clin Toxicol 2003 41 : 901 2.
28. McCall M Bourgeois JA. Valproic acid-induced hyperammonemia: a case report. J Clin Psychopharmacol 2004 24 : 521 6.
29. Vossler DG Wilensky AJ Cawthon DF et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia 2002 43 : 154 9.
30. Averbuch-Heller L Ben-Hur T Reches A. Valproate encephalopathy and hypocarnitinaemia in diabetic patients. J Neurol 1994 241 : 567 9.
31. Felipo V Butterworth RF. Neurochemistry of ammonia. Neurochem Int 2002 41 : 79.
32. Llansola M Erceg S Hernández-Viadel M Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis 2002 17 : 389 97.
33. Suárez I Bodega G Fernández B. Glutamine synthetase in brain: effect of ammonia. Neurochem Int 2002 41 : 123 42.
34. Gail E Solomon GE. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 55 : 606.
35. Shakoor KA Khan K. Valproic acid-induced hepatotoxicity and protective role of carnitina. Pakistan J Pathol 1997 8 : 133 4.
36. Lokrantz CM Eriksson B Rosen I Asztely F. Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam. Acta Neurol Scand 2004 109 : 297 301.
37. Uetrecht JP. Salicylate potentiates valproate-induced hyperammonemia in the rat. Pharmacology 1987 34 : 279 85.
38. Basile AS. Direct and indirect enhancement of GABAergic neurotransmission by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Neurochem Int 2002 41 : 115 22.
39. Brusilow SW. Hyperammonemic encephalopathy. Medicine 2002 81 : 240 9.
40. Takahashi H Koehler RC Brusilow SW Traystman RJ. Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats. Am J Physiol Heart Circ Physiol 1991 261 : 825 9.
41. Willard-Mack CL Koehler RC Hirata T et al. Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat. Neuroscience 1996 71 : 589 99.
42. Sheffali G Shaji M Madhulika K Veena K. Intermittent hyperammonemic encephalopathy in a child with ornithine transcarbamylase deficiency. Indian J Pediatr 2004 71 : 645 8.